MX2024003119A - Sstr4 agonist salts. - Google Patents
Sstr4 agonist salts.Info
- Publication number
- MX2024003119A MX2024003119A MX2024003119A MX2024003119A MX2024003119A MX 2024003119 A MX2024003119 A MX 2024003119A MX 2024003119 A MX2024003119 A MX 2024003119A MX 2024003119 A MX2024003119 A MX 2024003119A MX 2024003119 A MX2024003119 A MX 2024003119A
- Authority
- MX
- Mexico
- Prior art keywords
- salts
- sstr4
- sstr4 agonist
- agonist salts
- azabicyclo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)ox y]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243785P | 2021-09-14 | 2021-09-14 | |
| PCT/US2022/076401 WO2023044326A1 (en) | 2021-09-14 | 2022-09-14 | Sstr4 agonist salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003119A true MX2024003119A (en) | 2024-04-09 |
Family
ID=83508479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003119A MX2024003119A (en) | 2021-09-14 | 2022-09-14 | Sstr4 agonist salts. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11834435B2 (en) |
| EP (1) | EP4402136A1 (en) |
| JP (2) | JP2024533482A (en) |
| KR (1) | KR20240056751A (en) |
| CN (1) | CN117940413A (en) |
| AR (1) | AR127055A1 (en) |
| AU (1) | AU2022348561B2 (en) |
| CA (1) | CA3231451A1 (en) |
| CL (2) | CL2024000683A1 (en) |
| CO (1) | CO2024003038A2 (en) |
| CR (1) | CR20240118A (en) |
| DO (1) | DOP2024000050A (en) |
| EC (1) | ECSP24020256A (en) |
| IL (1) | IL311251A (en) |
| MX (1) | MX2024003119A (en) |
| PE (1) | PE20240885A1 (en) |
| TW (3) | TWI860849B (en) |
| WO (1) | WO2023044326A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI860849B (en) * | 2021-09-14 | 2024-11-01 | 美商美國禮來大藥廠 | Sstr4 agonist salts |
| US20240307349A1 (en) * | 2023-03-10 | 2024-09-19 | Eli Lilly And Company | Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof |
| WO2025096300A1 (en) * | 2023-10-30 | 2025-05-08 | Eli Lilly And Company | Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives |
| WO2025193591A1 (en) | 2024-03-11 | 2025-09-18 | Eli Lilly And Company | Crystalline form of a tartrate salt of an sstr4 agonist |
| GB202408483D0 (en) | 2024-06-13 | 2024-07-31 | Maxion Therapeutics Ltd | Receptor agonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159941A (en) | 1996-05-14 | 2000-12-12 | Novo Nordisk A/S | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| US6063796A (en) | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
| KR100895968B1 (en) | 2002-11-27 | 2009-05-07 | 인사이트 코포레이션 | 3-Aminopyrrolidine derivatives as modulators of chemokine receptors |
| FI20031454A0 (en) | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Selective somatostatin receptor 1 and / or 4 agonists and antagonists |
| US20100004339A1 (en) | 2003-10-06 | 2010-01-07 | Oy Juvantia Pharma Ltd. | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
| ES2634841T3 (en) | 2003-10-14 | 2017-09-29 | Pfizer Products Inc. | Bicyclic derivatives [3.1.0] as glycine transporter inhibitors |
| US20080300251A1 (en) | 2005-09-05 | 2008-12-04 | Sattigeri Jitendra A | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors |
| GB0616574D0 (en) | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| JP2010513458A (en) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Nicotinamide derivatives as inhibitors of H-PGDS and their use to treat prostaglandin D2-mediated diseases |
| JP2011527345A (en) | 2008-07-07 | 2011-10-27 | ファスジェン， インコーポレイテッド | NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND, METHOD OF USING THE COMPOUND, AND METHOD FOR PREPARING THE COMPOUND |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| JP2013542929A (en) | 2010-09-28 | 2013-11-28 | パナセア バイオテック リミテッド | New bicyclo ring compounds |
| WO2012125661A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists |
| CN102675290B (en) | 2011-03-18 | 2014-11-12 | 山东亨利医药科技有限责任公司 | Bicyclic dihydropyrazole compounds |
| KR101556318B1 (en) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | Novel 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| US10183940B2 (en) | 2014-11-14 | 2019-01-22 | Boehringer Ingelheim International Gmbh | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists |
| CA2965566A1 (en) | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists |
| AU2021276301A1 (en) | 2020-05-21 | 2023-01-19 | Guangzhou Fermion Technology Co., Ltd. | Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof |
| CN113717161B (en) | 2020-05-21 | 2023-06-09 | 广州费米子科技有限责任公司 | Nitrogen-containing saturated heterocyclic compound, preparation method thereof, pharmaceutical composition and application |
| WO2022012534A1 (en) | 2020-07-13 | 2022-01-20 | 广州费米子科技有限责任公司 | Nitrogen-containing heterocyclic compound, pharmaceutical composition, and applications |
| TWI860849B (en) * | 2021-09-14 | 2024-11-01 | 美商美國禮來大藥廠 | Sstr4 agonist salts |
-
2022
- 2022-09-13 TW TW112136333A patent/TWI860849B/en active
- 2022-09-13 TW TW111134517A patent/TWI822326B/en active
- 2022-09-13 AR ARP220102484A patent/AR127055A1/en unknown
- 2022-09-13 TW TW113126835A patent/TW202444703A/en unknown
- 2022-09-14 KR KR1020247011858A patent/KR20240056751A/en active Pending
- 2022-09-14 WO PCT/US2022/076401 patent/WO2023044326A1/en not_active Ceased
- 2022-09-14 JP JP2024516362A patent/JP2024533482A/en active Pending
- 2022-09-14 PE PE2024000415A patent/PE20240885A1/en unknown
- 2022-09-14 US US17/944,429 patent/US11834435B2/en active Active
- 2022-09-14 CN CN202280062405.0A patent/CN117940413A/en active Pending
- 2022-09-14 EP EP22783267.2A patent/EP4402136A1/en active Pending
- 2022-09-14 AU AU2022348561A patent/AU2022348561B2/en active Active
- 2022-09-14 CR CR20240118A patent/CR20240118A/en unknown
- 2022-09-14 CA CA3231451A patent/CA3231451A1/en active Pending
- 2022-09-14 IL IL311251A patent/IL311251A/en unknown
- 2022-09-14 MX MX2024003119A patent/MX2024003119A/en unknown
-
2023
- 2023-08-07 US US18/366,218 patent/US12486249B2/en active Active
-
2024
- 2024-03-06 CL CL2024000683A patent/CL2024000683A1/en unknown
- 2024-03-13 CO CONC2024/0003038A patent/CO2024003038A2/en unknown
- 2024-03-14 DO DO2024000050A patent/DOP2024000050A/en unknown
- 2024-03-14 EC ECSENADI202420256A patent/ECSP24020256A/en unknown
-
2025
- 2025-04-23 JP JP2025071176A patent/JP2025111617A/en active Pending
- 2025-07-22 CL CL2025002158A patent/CL2025002158A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330492A (en) | 2023-08-01 |
| CO2024003038A2 (en) | 2024-04-18 |
| US20230099116A1 (en) | 2023-03-30 |
| US20240067628A1 (en) | 2024-02-29 |
| CL2025002158A1 (en) | 2025-11-07 |
| TW202400577A (en) | 2024-01-01 |
| TWI822326B (en) | 2023-11-11 |
| AR127055A1 (en) | 2023-12-13 |
| AU2022348561A1 (en) | 2024-03-14 |
| US12486249B2 (en) | 2025-12-02 |
| CL2024000683A1 (en) | 2024-08-23 |
| CN117940413A (en) | 2024-04-26 |
| CR20240118A (en) | 2024-04-25 |
| TW202444703A (en) | 2024-11-16 |
| CA3231451A1 (en) | 2023-03-23 |
| JP2025111617A (en) | 2025-07-30 |
| WO2023044326A1 (en) | 2023-03-23 |
| TWI860849B (en) | 2024-11-01 |
| EP4402136A1 (en) | 2024-07-24 |
| KR20240056751A (en) | 2024-04-30 |
| AU2022348561B2 (en) | 2025-05-22 |
| IL311251A (en) | 2024-05-01 |
| DOP2024000050A (en) | 2024-04-30 |
| PE20240885A1 (en) | 2024-04-24 |
| JP2024533482A (en) | 2024-09-12 |
| US11834435B2 (en) | 2023-12-05 |
| ECSP24020256A (en) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003119A (en) | Sstr4 agonist salts. | |
| CY1112505T1 (en) | Immunosuppressive compounds and compositions | |
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| MY147767A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| MA29088B1 (en) | INDAZOLE-CARBOXAMIDE COMPOUNDS. | |
| TNSN05294A1 (en) | Immunosuppressant compounds and compositions | |
| MXPA05012461A (en) | Immunosuppressant compounds and compositions. | |
| CN104703605A (en) | Treatment of immune-related and inflammatory diseases | |
| EE04911B1 (en) | The compound and the pharmaceutical composition as protease inhibitors, their use and a method for preparing the compound | |
| PH12019502154A1 (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| CY1111070T1 (en) | 2-AMINE-QUINAZOLINE DERIVATIVE USEFUL FOR B-SECRETARISE INHIBITORS (BACE) | |
| CY1111733T1 (en) | 2- (1H-INDOLYSULFANYL) -BENZYLAMINE PRODUCTION AS SSRI | |
| TW200505416A (en) | Bi-aryl compound having immunosuppressive activity | |
| NO20061737L (en) | Amino-substituted erylamino B2 adrenergic receptor agonists | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| MX2022003243A (en) | Anti-ptcra antibody-drug conjugates and uses thereof. | |
| MX2021006682A (en) | Decarboxylase inhibitors for treating parkinson's disease. | |
| NO20064238L (en) | Imidazoline derivatives with CB1 agonist activity | |
| MX2013002649A (en) | Therapeutic agent for pain. | |
| NO20061575L (en) | Process for the preparation of renzapride and its intermediates | |
| WO2023034645A3 (en) | Asymmetric allyl tryptamines | |
| WO2025076071A3 (en) | Synthesis of ras inhibitors | |
| WO2025029832A3 (en) | Sting agonist compounds and conjugates | |
| MX2025013377A (en) | 5,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators | |
| WO2020077094A8 (en) | Tca cycle intermediates and methods of use thereof |